Swiss National Bank’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-83,000
| Closed | -$4.88M | – | 2552 |
|
|
2023
Q4 | $4.88M | Sell |
83,000
-28,800
| -26% | -$1.62M | ﹤0.01% | 1310 |
|
|
2023
Q3 | $4.87M | Buy |
111,800
+23,200
| +26% | +$828K | ﹤0.01% | 1296 |
|
|
2023
Q2 | $3.2M | Buy |
88,600
+1,600
| +2% | +$65.9K | ﹤0.01% | 1593 |
|
|
2023
Q1 | $3.23M | Sell |
87,000
-7,000
| -7% | -$315K | ﹤0.01% | 1542 |
|
|
2022
Q4 | $4.26M | Buy |
94,000
+1,800
| +2% | +$116K | ﹤0.01% | 1424 |
|
|
2022
Q3 | $6.44M | Buy |
92,200
+900
| +1% | +$66.6K | ﹤0.01% | 1127 |
|
|
2022
Q2 | $6.13M | Hold |
91,300
| – | – | ﹤0.01% | 1204 |
|
|
2022
Q1 | $7.51M | Buy |
91,300
+11,800
| +15% | +$1.21M | ﹤0.01% | 1194 |
|
|
2021
Q4 | $11.7M | Sell |
79,500
-100
| -0.1% | -$15.5K | 0.01% | 924 |
|
|
2021
Q3 | $14.1M | Buy |
79,600
+1,500
| +2% | +$241K | 0.01% | 817 |
|
|
2021
Q2 | $12.6M | Sell |
78,100
-2,300
| -3% | -$369K | 0.01% | 901 |
|
|
2021
Q1 | $13.8M | Buy |
80,400
+14,900
| +23% | +$2.95M | 0.01% | 839 |
|
|
2020
Q4 | $14.4M | Buy |
65,500
+1,200
| +2% | +$259K | 0.01% | 760 |
|
|
2020
Q3 | $10.7M | Buy |
64,300
+1,200
| +2% | +$164K | 0.01% | 782 |
|
|
2020
Q2 | $7.2M | Buy |
63,100
+13,400
| +27% | +$1.3M | 0.01% | 945 |
|
|
2020
Q1 | $3.82M | Buy |
49,700
+800
| +2% | +$71.7K | ﹤0.01% | 1070 |
|
|
2019
Q4 | $6.3M | Buy |
48,900
+5,000
| +11% | +$482K | 0.01% | 1008 |
|
|
2019
Q3 | $3.42M | Buy |
43,900
+1,200
| +3% | +$113K | ﹤0.01% | 1334 |
|
|
2019
Q2 | $4.4M | Buy |
42,700
+7,100
| +20% | +$553K | ﹤0.01% | 1202 |
|
|
2019
Q1 | $2.61M | Buy |
35,600
+1,300
| +4% | +$88.4K | ﹤0.01% | 1491 |
|
|
2018
Q4 | $1.46M | Buy |
34,300
+4,000
| +13% | +$159K | ﹤0.01% | 1770 |
|
|
2018
Q3 | $1.43M | Hold |
30,300
| – | – | ﹤0.01% | 1935 |
|
|
2018
Q2 | $1.49M | Buy |
+30,300
| New | +$1.14M | ﹤0.01% | 1911 |
|
|
2016
Q4 | – | Sell |
-21,000
| Closed | -$139K | – | 2572 |
|
|
2016
Q3 | $139K | Hold |
21,000
| – | – | ﹤0.01% | 2526 |
|
|
2016
Q2 | $115K | Hold |
21,000
| – | – | ﹤0.01% | 2573 |
|
|
2016
Q1 | $434K | Buy |
21,000
+4,900
| +30% | +$110K | ﹤0.01% | 2379 |
|
|
2015
Q4 | $509K | Hold |
16,100
| – | – | ﹤0.01% | 2253 |
|
|
2015
Q3 | $554K | Buy |
16,100
+7,500
| +87% | +$227K | ﹤0.01% | 2136 |
|
|
2015
Q2 | $271K | Buy |
+8,600
| New | +$253K | ﹤0.01% | 2479 |
|
Other funds holding MRTX
Swiss National Bank's MRTX Position: Q1 2024 in Review
Swiss National Bank sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 83,000 shares — an estimated $4.88M sold.
Swiss National Bank first reported a position in MRTX in Q2 2015 and held it in 29 quarters. The position peaked at $14.4M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Swiss National Bank reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Swiss National Bank sold 83,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.88M.
- Swiss National Bank first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 29 quarters.
- Swiss National Bank's Mirati Therapeutics, Inc. Common Stock position peaked at $14.4M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Swiss National Bank's 13F filing for Q1 2024, filed 7 May 2024.